clinical trials

Pfizer ticks off Lyme vaccine milestone, linking booster shot to pediatric antibody response
Pfizer ticks off Lyme vaccine milestone, linking booster shot to pediatric antibody response
Fierce Biotech
Pfizer
Lyme disease
vaccines
pediatric
clinical trials
VLA15
Valneva
Flag link:
BioCardia’s Cell Therapy Unlikely to Meet Primary Endpoint in Phase III Heart Failure
BioCardia’s Cell Therapy Unlikely to Meet Primary Endpoint in Phase III Heart Failure
BioSpace
BioCardia
clinical trials
cell therapy
heart failure
CardiAMP
Flag link:
Vaccine experts urge more inclusivity in clinical trials
Vaccine experts urge more inclusivity in clinical trials
Stat
vaccines
RSV
clinical trials
inclusivity
Flag link:
Beam Therapeutics starts dosing in phase 1/2 trial of BEAM-201 in relapsed, refractory T-ALL/T-LL
Beam Therapeutics starts dosing in phase 1/2 trial of BEAM-201 in relapsed, refractory T-ALL/T-LL
Benzinga
Beam Therapeutics
clinical trials
CAR-T
BEAM-201
T-ALL
T-LL
Flag link:
Genmab and Seagen’s TIVDAK trial meets primary endpoint
Genmab and Seagen’s TIVDAK trial meets primary endpoint
Clinical Trials Arena
Genmab
Seagen
Tivdak
clinical trials
cervical cancer
Flag link:
Bayer looks to expand Kerendia label to include heart failure
Bayer looks to expand Kerendia label to include heart failure
Clinical Trials Arena
Bayer
Kerendia
clinical trials
heart failure
Flag link:
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Clinical Trials Arena
Eli Lilly
retatrutide
clinical trials
NASH
obesity
diabetes
type 2 diabetes
Flag link:
FibroGen fails again in DMD, continuing rotten run of phase 3 flops
FibroGen fails again in DMD, continuing rotten run of phase 3 flops
Fierce Biotech
FibroGen
Duchenne Muscular Dystrophy
clinical trials
pamrevlumab
Flag link:
Clene polishes tarnished ALS asset with long-term survival data
Clene polishes tarnished ALS asset with long-term survival data
Fierce Biotech
Clene
ALS
clinical trials
CNM-Au8
Flag link:
Lilly’s Cholesterol Pill Shows Early Promise in Phase I Study
Lilly’s Cholesterol Pill Shows Early Promise in Phase I Study
BioSpace
Eli Lilly
muvalaplin
clinical trials
cholesterol
Flag link:
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Drugs.com
Merck
clinical trials
MK-0616
hypercholesterolemia
Flag link:
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
MedCity News
Bayer
cell therapy
Parkinson's Disease
clinical trials
Flag link:
Novartis: Leqvio Provides Low-density Lipoprotein Cholesterol Reduction Beyond 6 Years Of Treatment
Novartis: Leqvio Provides Low-density Lipoprotein Cholesterol Reduction Beyond 6 Years Of Treatment
RTT News
Novartis
Leqvio
LDL cholesterol
clinical trials
Flag link:
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Amgen
cardiovascular disease
olpasiran
clinical trials
Flag link:
FDA grants clearance to Harbour’s IND for solid tumors therapy trial
FDA grants clearance to Harbour’s IND for solid tumors therapy trial
Clinical Trials Arena
Harbour BioMed
clinical trials
HBM9033
solid tumors
Flag link:
Valneva reports data from chikungunya vaccine trial in adolescents
Valneva reports data from chikungunya vaccine trial in adolescents
Clinical Trials Arena
Valneva
clinical trials
VLS1553
chikungunya virus
Flag link:
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
head and neck cancer
Flag link:
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Yahoo/GlobeNewswire
Bridge Bio
clinical trials
acoramidis
ATTR
ATTR-CM
Flag link:
On a roll, Novo's star obesity drug Wegovy shows benefits in patients with heart failure
On a roll, Novo's star obesity drug Wegovy shows benefits in patients with heart failure
Fierce Pharma
Novo Nordisk
Wegovy
heart failure
clinical trials
Flag link:
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program
Fierce Biotech
Merck
PCSK9 inhibitors
clinical trials
cardiovascular disease
cholesterol
MK-0616
Flag link:

Pages